JPM vs MRK: Which Is the Better Buy?
Side-by-side comparison of JPMorgan Chase & Co. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
JPMorgan Chase & Co. · Financial Services
$316.99
+45.0% upside to fair value
Grade C
High Quality
VS
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
QuantHub Verdict
JPM has more upside to fair value
(+45.0%).
JPM trades at a lower forward P/E
(15.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JPM |
MRK |
| Current Price |
$316.99 |
$114.27 |
| Fair Value Estimate |
$459.64 |
$118.00 |
| Upside to Fair Value |
+45.0%
|
+3.3%
|
| Market Cap |
$854.9B |
$282.2B |
| Forward P/E |
15.0x
|
22.4x
|
| EV / EBITDA |
21.8x
|
13.5x
|
| Price / Sales |
3.0x
|
4.3x
|
| Price / FCF |
8.5x
|
20.2x
|
| Revenue Growth YoY |
+6.9%
|
+5.0%
|
| Gross Margin |
60.9%
|
81.9%
|
| Operating Margin |
26.2%
|
27.5%
|
| Return on Equity |
16.3%
|
5.6%
|
| Dividend Yield |
0% |
2.91% |
| FCF Yield |
11.79%
|
4.95%
|
| Analyst Consensus |
Buy
|
Overweight
|
Investment Thesis
JPMorgan Chase & Co. is a leading diversified financial services firm with a strong competitive moat driven by its scale, diversified revenue streams, and long-tenured leadership. The company operates across four main segments: Commercial & Investment Bank, Consumer & Community Banking, Asset & Wealth Management, and Corporate, generating $279.75 billion in revenue in fiscal 2025. Its durable com…
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Accumulation Zones
| Metric |
JPM |
MRK |
| Zone Low |
$344.73 |
$88.50 |
| Zone High |
$390.69 |
$100.30 |
| In Buy Zone? |
Yes
|
No
|